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In Brief
Acetyl-CoA synthetase 2 (ACSS2)
generates acetyl-CoA from acetate and is
important for tumor growth. Bulusu et al.
show that, in hypoxic tumor regions,
ACSS2 is prominently expressed in the
nuclei of tumor cells. Here it maintains
histone acetylation by recapturing
acetate released by histone deacetylases
so it can be re-used for acetylation.
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Acetyl-CoA is a key metabolic intermediate with
an important role in transcriptional regulation. The
nuclear-cytosolic acetyl-CoA synthetase 2 (ACSS2)
was found to sustain the growth of hypoxic tumor
cells. It generates acetyl-CoA from acetate, but
exactly which pathways it supports is not fully under-
stood. Here, quantitative analysis of acetate meta-
bolism reveals that ACSS2 fulfills distinct functions
depending on its cellular location. Exogenous ace-
tate uptake is controlled by expression of both
ACSS2 and the mitochondrial ACSS1, and ACSS2
supports lipogenesis. The mitochondrial and lipo-
genic demand for two-carbon acetyl units consid-
erably exceeds the uptake of exogenous acetate,
leaving it to only sparingly contribute to histone acet-
ylation. Surprisingly, oxygen and serum limitation in-
crease nuclear localization of ACSS2. We find that
nuclear ACSS2 recaptures acetate released from his-
tone deacetylation for recycling by histone acetyl-
transferases. Our work provides evidence for limited
equilibration between nuclear and cytosolic acetyl-
CoA and demonstrates that ACSS2 retains acetate
to maintain histone acetylation.INTRODUCTION
Cancer is a disease of unrestrained cell proliferation. This ne-
cessitates the continued production of cellular components,
including lipid membranes, for the generation of daughter cells
(DeBerardinis et al., 2008). The bulk elements of membranes
are fatty acids, and their de novo synthesis by cancer cells pla-
ces a high demand on the precursor acetyl-coenzyme A (AcCoA)
(Menendez and Lupu, 2007; Currie et al., 2013). In addition to its
role in biomass production, the central position of AcCoA in both
anabolic and catabolic pathways makes it a rheostat of theCell
This is an open access article undmetabolic state of the cell (Pietrocola et al., 2015; Shi and Tu,
2015; Fan et al., 2015). AcCoA abundance directly affects the
metabolic activity of many enzymes, and acetylation events on
histones and other proteins control cellular functions at the tran-
scriptional and post-translational levels. Disrupting acetylation
homeostasis by inhibiting deacetylases (i.e., histone deacety-
lases [HDACs] and sirtuins) was shown to influence cancer cell
survival (Falkenberg and Johnstone, 2014). It is therefore crucial
for cells to maintain AcCoA homeostasis.
In solid tumors, cells frequently experience reduced oxygen
availability because of aberrant vascularization (Brown and Wil-
son, 2004). Although, in oxygenated cells, most AcCoA is made
from glucose, during hypoxia, stabilization of HIF1 causes can-
cer cells to shunt most glucose-derived carbon toward lactate
(Kim et al., 2006; Papandreou et al., 2006). This diminishes
AcCoA production from glucose, and how cancer cells adapt
has been a topic of interest. Tracing experiments revealed
that glutamine, through reductive carboxylation, is a precursor
for AcCoA that is used for fatty acid biosynthesis, also known
as lipogenic AcCoA (Wise et al., 2011; Metallo et al., 2011;
Mullen et al., 2011). It has later been argued that a reduction
in citrate levels in hypoxic cells causes increased reversibility
with a-ketoglutarate. Because of this, at least some fatty acid
labeling from glutamine could be explained as isotope ex-
change (i.e., mixing of label) rather than a net reductive flux
(Fan et al., 2013).
More recently, it was found that 13C-acetate significantly la-
bels the lipogenic AcCoA pool of hypoxic cells (Kamphorst
et al., 2014) and, consequently, lipids (Schug et al., 2015), sug-
gesting that acetate can act as an alternative carbon source
for biomass production under these conditions. In a separate
study, glioblastomas and brain metastases were shown to
oxidize acetate for energy production, indicating that the meta-
bolic fate may depend on tumor type (Mashimo et al., 2014).
Importantly, silencing the nuclear-cytosolic isoform of AcCoA
synthetase (ACSS2), which converts acetate to AcCoA, reduced
tumor growth in a xenograft model of breast cancer (Schug et al.,
2015). Furthermore, ACSS2 deletion diminished tumor burden in
a genetically engineered mouse model of hepatocellular carci-
noma (Comerford et al., 2014).Reports 18, 647–658, January 17, 2017 ª 2017 The Author(s). 647
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Figure 1. ACSS2 Controls Acetate Incorpo-
ration Into Lipogenic Acetyl-CoA
(A) Schematic of lipogenic AcCoA production.
(B) Steady-state 13C labeling (percent) of lipogenic
AcCoA from 90 mMU-13C-acetate (Ac) in normoxia
or hypoxia (1% O2).
(C) Steady-state 13C labeling (percent) of lipogenic
AcCoA from U-13C-glucose (Gluc), U-13C-gluta-
mine (Gln), and 90 mM U-13C-acetate.
(D) Western blot of ACSS2 from cells transfected
with scrambled RNA (SCR) or two independent
ACSS2 siRNAs. The normalized ratio is relative to
the SCR control.
(E) Steady-state 13C labeling (percent) of lipogenic
AcCoA from 90 mM U-13C-Ac in hypoxic SCR or
ACSS2 siRNA-treated cells.
(F) Steady-state 13C labeling (percent) of lipogenic
AcCoA from U-13C-Gluc and U-13C-Gln in hypoxic
SCR or ACSS2 siRNA-treated cells. The medium
contained 90 mM 12C-acetate.
(G) ACSS2 western blot from multiple human
cancer cell lines under hypoxia (48 hr). Tubulin was
used as the loading control.
(H) Steady-state 13C labeling (percent) of lipogenic
AcCoA from 500 mM U-13C-Acetate.
(B–F) Experiments were done in MDA-MB-468
cells.
All data are mean ± SD (n = 3); *p < 0.05, **p < 0.01.
See also Figure S1.The extensive fatty acid labeling from 13C-acetate in hypoxic
cancer cells may indicate that the increased ACSS2 expression
supports biomass production. It is important to note, however,
that the actual carbon contribution to fatty acid synthesis re-
mains to be determined. As with glutamine, the fractional label-
ing of AcCoA from acetate may not reflect net synthesis because
of isotope exchange (Fan et al., 2013). A rapid equilibration be-
tween the acetate and AcCoA pools could occur as a conse-
quence of a fast protein acetylation-deacetylation cycle, with
the cellular acetate pool also exchanging with labeled medium
acetate. This would result in pronounced labeling of AcCoA
and, subsequently, fatty acids from 13C-acetate without a net
carbon transfer. Therefore, a more extensive evaluation to quan-
tify the contribution of acetate to biomass production is needed.
Furthermore, it has been reported that a significant proportion of
ACSS2 localizes to the nuclei of tumor cells (Comerford et al.,
2014), and how much exogenous acetate can contribute to nu-
clear processes such as histone acetylation remains unknown.
Here we apply innovative stable isotope tracing and mass
spectrometry approaches to quantify acetate consumption and
utilization by downstream pathways in a panel of cancer cell lines
with varying levels of ACSS2 expression. We find that the com-
bined expression of ACSS1 and ACSS2 determines the net ace-
tate uptake rate. Exogenous acetate is used extensively by the
mitochondria and for lipogenesis, and the demand for acetate
substantially exceeds its uptake. As a consequence, exogenous
acetate only modestly labels histone-bound acetate. However,648 Cell Reports 18, 647–658, January 17, 2017nuclear localization of ACSS2 increases
during oxygen and serum limitation, and
nuclear ACSS2 is prominent in poorlyperfused, hypoxic tumor regions of a mouse model of breast
cancer. We find that the primary function of nuclear ACSS2 is
to retain endogenous acetate released by deacetylases to main-
tain histone acetylation and propose that this is especially rele-
vant in hypoxic and nutrient-limited areas of the tumor.
RESULTS
ACSS2 Expression Dictates Lipogenic AcCoA Labeling
from U-13C-Acetate in Hypoxic Cancer Cells
A substantial fraction of the AcCoA used for fatty acid biosyn-
thesis (i.e., lipogenic AcCoA) is produced from glucose and
glutamine (Figure 1A). Alternatively, lipogenic AcCoA can be
produced from acetate by ACSS2, and this pathway has been
reported to be induced in hypoxic tumor cells (Schug et al.,
2015; Comerford et al., 2014). Importantly, we determine the
contribution of these different precursors to lipogenic AcCoA
from fatty acid labeling without the need to analyze AcCoA
directly, which is a mixture of all pools in the cell (Kamphorst
et al., 2014; Tumanov et al., 2015).
We previously reported a substantial contribution of acetate to
lipogenic AcCoA in hypoxic cancer cells, including MDA-MB-
468 breast cancer cells (Kamphorst et al., 2014). Because the
concentration of acetate in human plasma is 50–250 mM (Schug
et al., 2015), we sought to confirm the propensity of these cells to
use acetate in the lower end of this physiological range. Nor-
moxic and hypoxic (1% O2) MDA-MB-468 cells were exposed
to 90 mM U-13C-acetate. Although a relatively small fraction of
lipogenic AcCoA labeled from U-13C-acetate in normoxic cells,
this increased to approximately 30% in hypoxia (Figure 1B).
Next, cells were cultured in the presence of U-13C-glucose,
U-13C-glutamine, and U-13C-acetate to confirm that, combined,
these are the major substrates for lipogenic AcCoA production
(Figure 1C). As expected, the contribution from glucose dropped
considerably in hypoxia, and labeling from both U-13C-glutamine
and U-13C-acetate increased. Under both conditions, the major-
ity of lipogenic AcCoAwas labeled from all substrates combined.
The somewhat lower labeling under hypoxic conditions could, in
part, be explained by the presence of residual unlabeled acetate
(15 mM) in the medium. Therefore, when provided in a physio-
logically relevant concentration, acetate is an important sub-
strate for lipogenic AcCoA.
ACSS2 is reportedly responsible for acetate utilization for lipo-
genesis, but an accurate quantitation of its contribution is lack-
ing. When silencing ACSS2 expression in MDA-MB-468 cells
using small interfering RNA (siRNA) (Figure 1D), we observed
a pronounced reduction in labeling of lipogenic AcCoA from
U-13C-acetate (Figure 1E). Similar results were obtained for
BT-474 cells (Figures S1A and S1B). Under these conditions, la-
beling from U-13C-glucose and U-13C-glutamine increased to
80% (Figure 1F). We found that unlabeled acetate in the
medium suppressed labeling of lipogenic AcCoA from U-13C-
glucose and U-13C-glutamine, indicating that acetate is prefer-
entially used for lipogenesis under these conditions (Figure S1C).
The increased labeling from U-13C-glucose and U-13C-gluta-
mine upon ACSS2 knockdown may not indicate increased
AcCoA biosynthesis from these substrates; net production
may remain equal while fractional labeling increases because
of the drop in the contribution from acetate. This supports earlier
findings that acetate, glucose, and glutamine are the main sub-
strates for lipogenic AcCoA (Kamphorst et al., 2014).
To further investigate the role of ACSS2 expression in acetate
utilization for lipogenic AcCoA, we performed U-13C-acetate
tracing in a set of six cancer cell lines originating from cervical
(HeLa), lung (A549), pancreatic (AsPC-1), and breast tumors
(MDA-MB-231, MDA-MB-468, and BT-474). This set covers a
wide range of ACSS2 expression and facilitates assessment of
the relation between ACSS2 expression and lipogenic AcCoA la-
beling in cells with the same or different tissue backgrounds (Fig-
ures 1G and 1H). Across cell lines, a clear correlation was found
between ACSS2 expression and lipogenic AcCoA labeling from
U-13C-acetate. ACSS1 expression generally appeared to be low
inmost cell lines, except for BT-474 cells (Figure S1D). In this cell
line, silencing ACSS1 had no effect on ACSS2 expression but did
cause a small increase in lipogenic AcCoA labeling from U-13C-
acetate (Figures S1E and S1F), perhaps because of some
degree of competition between ACSS1 and ACSS2 for the
available acetate. Together, these results show a strong correla-
tion between ACSS2 expression and lipogenic AcCoA labeling
from U-13C-acetate.
Cancer Cells Exchange Acetate with the Medium, and
Net Exchange Is Determined by ACSS2 Expression
As stated earlier, fatty acid labeling from U-13C-acetate is not
sufficient to determine the carbon contribution from acetatebecause of possible cycling and exchange (Fan et al., 2013;
Kamphorst et al., 2014). To measure acetate directly and quan-
tify its net uptake by cancer cells, we developed amethod based
on alkylation of acetate to its propyl ester derivative using a
methyl chloroformate (MCF)-catalyzed derivatization reaction
and subsequent gas chromatography-mass spectrometry (GC-
MS) analysis (Experimental Procedures; Figure S2A; Tumanov
et al., 2016). For our analyses, we used 2H3-acetate as an internal
standard, enabling within-run quantification of both 12C-acetate
and U-13C-acetate. We applied this method to analyze uptake of
90 mM U-13C-acetate spiked into the medium by both normoxic
and hypoxic MDA-MB-468 cells. The hypoxic cells consumed
almost all U-13C-acetate (Figure 2A). Interestingly, although, in
normoxic cells, lipogenic AcCoA labeled only marginally from
acetate (Figure 1B), U-13C-acetate uptake was comparable
with hypoxic cells.
To our surprise, in addition to a reduction in U-13C-acetate
because of consumption, unlabeled acetate (12C-acetate)
accumulated in the cell-conditioned medium (Figure 2B). We
concluded that this acetate was being released by cells because
the initial medium 12C-acetate and U-13C-acetate concentra-
tions remained stable when incubated in the absence of cells
(Figure S2B). Furthermore, this acetate labeled from U-13C-
glucose and U-13C-glutamine (Figure S2C). Acetate release
was approximately equal to acetate consumption, resulting in
an unchanged total medium acetate concentration (Figure 2C).
This was also observed with physiological concentrations of
glucose (5.5 mM) and glutamine (0.65 mM) (Figure S2D). Under
the conditions described here, lipogenic AcCoA and, hence,
fatty acid labeling fromU-13C-acetatewasprominent (Figure 1B).
However, because no net uptake of acetate could be observed,
it is caused by cycling between acetate and lipogenic AcCoA
and exchange between cellular and medium acetate.
To expand our analysis of acetate uptake (u), release (r), and
net exchange (e) flux independently of cell number and growth,
we cultured cells in medium containing various concentrations
of U-13C-acetate. The net exchange rate was calculated as the
change in total medium acetate divided by the area under the
cell growth curve. To deconvolute the uptake and release com-
ponents of the exchange, we used the balance equations for the
exchange of total acetate (e = r  u) and 12C-acetate (xe = ar 
bu), where x is the concentration change in medium 12C-acetate
relative to the concentration change of total acetate, a is the
average 12C-acetate fraction inside cell, and b is the average
12C-acetate fraction in the medium. The parameters e, x, and b
can be estimated from the measurement of medium 12C- and
U-13C-acetate at different time points (see Supplemental Exper-
imental Procedures for more information). The intracellular free
acetate concentration was too low to quantify accurately. We
therefore considered all biologically relevant values of the intra-
cellular acetate fractions (Supplemental Experimental Proced-
ures). Under all conditions tested, both uptake and release of
acetate were 3–4 mmol/hr/L cell volume, with little variation
because of extracellular acetate concentration or oxygenation
(Figure 2D). In contrast, the net exchange rate remained close
to zero, with a tendency toward net acetate release.
We expanded our net acetate exchange experiments to the
panel of six cancer cell lines (Figure 1G) cultured in hypoxiaCell Reports 18, 647–658, January 17, 2017 649
Figure 2. Cancer Cells Take up and Release
Acetate, and ACSS2 Expression Dictates
Net Exchange
(A) Time course of U-13C-Ac (90 mM) uptake by
MDA-MB-468 cells in normoxia and hypoxia.
(B) Time course of unlabeled (12C) Ac release into
the medium.
(C) Time course of total Ac (U-13C-Ac + 12C-Ac)
concentration in medium.
(D) Estimated acetate release, uptake, and ex-
change fluxes in normoxic (blue) and hypoxic (red)
MDA-MB-468 cells for multiple concentrations of
U-13C-Ac in the medium. The open bars represent
the 5% quantile of the acetate release flux (i.e.,
with 95% confidence, the release flux is higher
than the bar height). The filled bars represent the
5% quantile of the acetate uptake flux (i.e., with
95% confidence, the uptake flux is higher than the
bar height). The dashed bars and error bars
represent the median and 95% confidence in-
tervals of the acetate exchange flux.
(E) Net acetate exchange for the panel of cell lines
in hypoxia and 10% or 1% dialyzed serum. Cell
lines are ordered based on increasing ACSS2
expression from left to right.
All data are mean ± SD (n = 3). See also Figure S2.and high (10%) or low (1%) serum (Figure 2E). The cell lines
with low ACSS2 expression (HeLa and A549) showed a net
release of acetate that was reduced in low serum. Generally,
culturing cells in low serum and hypoxia caused induction of
ACSS2 expression (Figure S2E; Schug et al., 2015), and this
led to a net acetate uptake for MDA-MB-231 and MDA-MB-
468 cells. For the latter, net exchange was comparable with
AsPC-1 cells, which have similar levels of ACSS2. BT-474 cells
express high levels of ACSS2 because of gene amplification
(Schug et al., 2015). They were found to most avidly take up
acetate, especially in low serum (8 mmol/hr/L cell volume).
Together, these results demonstrate that cells exchange ace-
tate with the medium and that high ACSS2 expression pro-
motes net acetate uptake.650 Cell Reports 18, 647–658, January 17, 2017Mitochondrial and Lipogenic
Utilization of Exogenous Acetate
Limits Its Use for Histone
Acetylation
Net acetate uptake is highest in low
serum, and this may be more reflective
of the tumor microenvironment. We
therefore used low serum for subsequent
analyses. After being activated to AcCoA,
exogenous acetate can be directed
toward mitochondria for oxidation (Ma-
shimo et al., 2014), used for biomass
production (particularly lipogenesis),
or used for acetylation. To determine
whether acetate feeds into mitochondria,
weanalyzed tricarboxylic acid (TCA) cycle
intermediate labeling fromU-13C-acetate.
Substantial (15%–25%) labeling occurredin BT-474 cells and, to a lesser extent, in MDA-MB-468 cells
despite the hypoxia and low serum (Figures 3A and 3B). ACSS1
is responsible for mitochondrial utilization of acetate, and its
knockdown substantially, although not completely, reduced la-
beling of TCA cycle intermediates (Figures S3A and S3D).
Conversely, overexpressing ACSS1 in MDA-MB-468 cells led
to an4-fold increase in labeling of TCAcycle intermediates (Fig-
ures S3B and S3C). In BT-474 cells, ACSS1 silencing caused a
concomitant reduction in exogenous acetate uptake by approx-
imately 30% (Figures 3C and 3D). Because ACSS1-generated
AcCoAdoesnot appear to feed into fatty acidbiosynthesis, it pro-
vides an estimate of mitochondrial acetate utilization.
A major AcCoA-consuming pathway in the cytosol is lipo-
genesis. To determine the AcCoA demand of this pathway,
Figure 3. High Mitochondrial and Lipogenic Demand for Acetate Limits Its Use for Histone Acetylation
(A and B) Steady-state labeling of TCA cycle intermediates from U-13C-Ac (500 mM) in (A) MDA-MB-468 cells and (B) BT-474 cells.
(C and D) Effect of ACSS1 knockdown on net acetate uptake in (C) MDA-MB-468 and (D) BT474 cells.
(E and F) Lipogenic AcCoA demand for de novo fatty acid synthesis as determined by kinetic flux profiling (Supplemental Experimental Procedures) for (E) MDA-
MB-468 and (F) BT-474 cells.
(G and H) Steady-state labeling of histone-bound acetate from U-13C-Gluc, U-13C-Gln, and U-13C-Ac for (G) MDA-MB-468 and (H) BT-474 cells.
(I) Effect of free fatty acid supplementation on fatty acid biosynthesis in MDA-MB-468 cells.
(J) Effect of free fatty acid supplementation on steady-state, histone-bound acetate labeling from U-13C-Ac in MDA-MB-468 cells.
For (A)–(D), (I), and (J), data are from cells in hypoxia (1% O2) and low serum (1%).
All data are mean ± SD (n = 3); *p < 0.05, **p < 0.01. See also Figure S3.we performed kinetic flux profiling by analyzing the incorpora-
tion of 13C from U-13C-glucose, U-13C-glutamine, and U-13C-
acetate into the palmitate pool over time (Supplemental Exper-
imental Procedures; Figures 3E and 3F; Tumanov et al., 2015).
The time-based label incorporation reflects the synthesis rate,
which can be deduced by fitting a differential equation (Yuan
et al., 2008). In agreement with previous reports, hypoxia
caused cells to reduce palmitate synthesis rates in the pres-
ence of high serum, particularly in MDA-MB-468 cells, because
of the presence of exogenous lipids (Kamphorst et al., 2013;Young et al., 2013). Exposing cells to low serum led to a potent
induction of the palmitate synthesis rate, increasing the de-
mand for lipogenic AcCoA. Strikingly, in low oxygen and serum,
the two-carbon acetyl demand for palmitate synthesis alone
outstripped the exogenous acetate uptake rate 2- to 3-fold.
The exact flux of acetate into lipogenesis could not be deter-
mined because of the exchange. However, labeling of lipogenic
AcCoA from U-13C-acetate is profound (Figure 1H), and
exogenous acetate suppresses labeling from U-13C-glucose
and U-13C-glutamine (Figure S1C). It is therefore likely that aCell Reports 18, 647–658, January 17, 2017 651
large proportion of the exogenous acetate is consumed for
lipogenesis.
Last, we determined histone-bound acetate labeling from
U-13C-glucose, U-13C-glutamine, or U-13C-acetate. We did this
by hydrolyzing acetate from purified histones rather than
measuring individual acetylated peptides (Experimental Proced-
ures). Therefore, the measured labeling reflects the aggregate of
the entire histone-bound acetate pool. Not surprisingly, glucose
was the major carbon donor under normoxic conditions (Figures
3G and 3H). In hypoxia and low serum, the contribution from
glucose dropped, and the percent labeling from U-13C-gluta-
mine increased 2-fold, indicating that reductive carboxylation
also occurs for histone acetylation (Figures 3G and 3H). Acetate
was the smallest contributor in both cell lines (<10%). Although
hypoxia and low serum caused this to increase to 15%, it
was still much less than either glucose and glutamine, and mul-
tiple-fold less than for lipogenic AcCoA (Figure 1H; Figure S3F).
ACSS1 overexpression in MDA-MB-468 cells did not affect this
(Figure S3E). Thus, exogenous acetate is inefficiently used for
histone acetylation.
We hypothesized that, upon cell entry, exogenous acetate
would be rapidly activated to AcCoA before being able to reach
the nucleus and that this AcCoA would locally feed into the car-
bon-demanding pathways of mitochondrial metabolism and lipo-
genesis rather than being used for histone acetylation. We there-
fore supplied the free fatty acids palmitate and oleate to cells to
reduce lipogenic demand for AcCoA. Free fatty acids are avidly
consumed by cells (Kamphorst et al., 2013), and this led to an
50% reduction in de novo lipogenesis (Figure 3I). This was
accompanied by a significant increase in labeling of histone-
boundacetate from theexogenouslysuppliedU-13C-acetate (Fig-
ure 3J). Thus, the high lipogenic consumption of exogenous ace-
tate at least partly explains its limited use for histone acetylation.
Oxygen and Serum Limitation Promote Nuclear
Localization of ACSS2, and ACSS2 Is Prominently
Nuclear in Hypoxic Tumor Regions
Although exogenous acetate is only sparingly used for histone
acetylation, ACSS2 has been reported to be substantially nu-
clear (Comerford et al., 2014). To quantify this, we performed
an analysis of ACSS2 localization in MDA-MB-468 cells using
immunofluorescence (Figures 4A and 4B). Under normoxic and
high serum conditions, 15% of the ACSS2 pool was localized
to the nucleus. However, exposing the cells to low serum and
oxygen caused a significant, 3-fold increase in the fraction of
nuclear ACSS2 (Figure 4B). A similar trend was observed for
BT-474 cells (Figure S4). Further assessment of the individual
factors indicated that both serum and oxygen limitation
contribute to the increased nuclear localization of ACSS2,
although the effect of serum limitation appeared to be strongest
(Figure 4B). Low glucose did increase the localization of ACSS2
to the nucleus in normoxic cells but not in hypoxic cells.
To determine the in vivo expression and localization of ACSS2
as a function of oxygenation, serial sections were prepared from
established tumors of the mousemammary tumor virus polyoma
middle T antigen (MMTV-PyMT) genetically engineered mouse
model of breast cancer (Guy et al., 1992). These were immuno-
stained for ACSS2, the hypoxic marker carbonic anhydrase IX652 Cell Reports 18, 647–658, January 17, 2017(CAIX), and the blood vessel marker CD31, in addition to H&E
staining (Figure 4C). Overall, ACSS2 staining was particularly
intense in hypoxic (high CAIX, low CD31) regions of the tumor
and exhibited prominent nuclear localization (Figure 4C). Indeed,
scoring of nuclear intensity of ACSS2 staining revealed that nu-
clear ACSS2 levels are substantially higher in hypoxic regions
than in perfused, normoxic regions (Figure 4D). These data
show that cultured cells in low oxygen and serum more strongly
resemble the conditions of the tumor with respect to ACSS2
localization. Additionally, it points to an important role for
ACSS2 in the nuclei of hypoxic tumor cells.
ACSS2 Recaptures Endogenously Produced Acetate
We considered whether the primary function of nuclear ACSS2
might be to recapture acetate released by histone deacetylation.
In support of an acetate-recapturing function of ACSS2, we
noticed that cells that avidly consumed U-13C-acetate released
relatively little 12C-acetate (Figure S5A), arguing that ACSS2 cap-
tures exogenous acetate but also prevents the release of endog-
enously produced acetate by recapturing it. To quantify endoge-
nous acetate release independently of cell number, we plotted
the ratio of 12C-acetate released versusU-13C-acetate consumed
in relation to ACSS2 expression for the six cell lines in our
panel. We found a strong inverse correlation between this ratio
and ACSS2 expression (Figure 5A), indicating that high ACSS2
expression not only facilitates uptake of exogenous acetate but
also efficient recapturing of endogenously produced acetate.
To further investigate the role of ACSS2 in recapturing endog-
enously produced acetate, we silenced its expression in MDA-
MB-468 cells by siRNA. In agreement with ACSS2mediating up-
take of exogenous acetate, this largely abrogated U-13C-acetate
consumption (Figure 5B). Consistent with the recapturing hy-
pothesis, 12C-acetate release markedly increased upon ACSS2
knockdown (Figure 5C). Under this serum- and oxygen-limited
condition, the net result was a stagnant total acetate level (Fig-
ure 5D). Further demonstrating that ACSS2 determines 12C-ace-
tate release/U-13C-acetate uptake, this ratio increased upon
ACSS2 knockdown in MDA-MB-468 and BT-474 cells (Figures
5E and 5F). A similar trend was observed in hypoxia and 10%
serum (Figures S5B and S5C). To determine whether ACSS1
recaptures endogenous acetate, we silenced its expression in
BT-474 cells. This also led to increased 12C-acetate release-
to-U-13C-acetate uptake ratio (Figure S5D). This demonstrates
that, in addition to taking up exogenous acetate, ACSS2 and
ACSS1 function to recapture endogenously produced acetate.
Net acetate uptake results from a combined intake of exogenous
acetate and retention of intracellular acetate.
ACSS2 Maintains Histone Acetylation during Oxygen
and Serum Limitation
The acetate re-capturing function of ACSS2 and its prominent
nuclear localization during oxygen and serum limitation promp-
ted us to test whether ACSS2 maintains histone acetylation.
This could be important because histones are among the most
abundant proteins in mammalian cells and are heavily acety-
lated. With a residence half-life of only minutes, turnover of
most histone acetylation marks is quite rapid (Evertts et al.,
2013). Under oxygen- and serum-replete conditions, silencing
Figure 4. ACSS2 Localizes to the Nucleus during Oxygen and Serum Limitation and Is Prominently Nuclear in Tumors
(A) Representative images of DAPI (nuclear) and ACSS2 staining (separately and merged) in MDA-MB-468 cells in normoxia and 10% serum or hypoxia and 1%
serum. Scale bar, 20 mm.
(B) Quantification of the nuclear fraction of ACSS2 (percent) in MDA-MB-468 cells cultured under different conditions. Data are mean ± SD of three independent
experiments (seven or more images per experiment).
(C) Immunohistochemical staining of serial sections from a representative tumor of the MMTV-PyMT mouse model for carbonic anhydrase 9 (CAIX, a hypoxic
marker), CD31 (a marker for blood vessels), ACSS2, and H&E staining.
(D) Scoring of ACSS2 nuclear intensity in normoxic and hypoxic tumor regions. Ten different ROIs were selected for normoxic and hypoxic regions of two tumors
(five ROIs each), and the percentages of cells with weak, moderate or strong nuclear ACSS2 staining were scored. Data are mean ± SD (n = 10 ROIs).
See also Figure S4.ACSS2 did not result in a decrease but, rather, a modest in-
crease in acetylation of histones H3 (AcH3) and H4 (AcH4) (Fig-
ures 6A and 6B), whichmay be due to HDAC inhibition by nuclear
acetate accumulation. In contrast, when silencing ACSS2 in low
oxygen and serum, a significant decrease was observed in the
acetylation of both H3 and H4. No acetate was added to the me-
dium in this experiment, further reinforcing the notion that
ACSS2 maintains histone acetylation by acetate recapturing.
We next asked whether any of the acetate released into the
medium originated from histone deacetylation. If so, then inhibi-tion of HDACs should lead to a drop in acetate release. We eval-
uated this with a short incubation protocol (6–8 hr depending on
the cell line). Incubation of MDA-MB-468 cells with the pan-
HDAC inhibitor panobinostat led to a significant reduction in ac-
etate release into the medium of the control (scramble [SCR])
MDA-MB-468 and BT-474 cells (Figures 6C and 6D; Figure S6A).
Comparable results were obtained with the HDAC inhibitor so-
dium butyrate (Figure S6B). As expected, silencing of ACSS2 re-
sulted in increased release of acetate. Importantly, treatment
with panobinostat in ACSS2-silenced cells caused a greaterCell Reports 18, 647–658, January 17, 2017 653
Figure 5. ACSS2 Recaptures Endogenously Produced Acetate
(A) Plot of the ratio of 12C-acetate released/13C-acetate consumed to ACSS2 expression in cancer cells in hypoxia and 10% or 1% dialyzed serum. Statistics are
from Pearson’s correlation analysis using GraphPad Prism software.
(B) Medium 13C-acetate consumption by siRNA-treated MDA-MB-468 cells exposed to hypoxia and 1% dialyzed serum.
(C) Medium 12C-acetate production in the same experiment.
(D) Total acetate in medium of the same experiment.
(E) Ratio of 12C-acetate released to/ 13C-acetate consumed by MDA-MB-468 cells treated with SCR or ACSS2 siRNAs.
(F) The same for BT-474 cells.
All data are mean ± SD (n = 3); *p < 0.05, **p < 0.01. See also Figure S5.absolute reduction in acetate release compared with SCR cells,
giving further credence to the acetate recapturing function of
ACSS2.We additionally tested the involvement of other enzymes
in acetate release. Incubation with the sirtuin inhibitors sirtinol
(Figure S6C) and nicotinamide (Figure S6D) led to a maximum
30% reduction in acetate release. In contrast, knockdown of
amino acid deacetylases aminoacylase 1 (ACY1) and ACY3,
which deacetylate free acetylated amino acids, and aspartoacy-
lase (ASPA), which deacetylates N-acetyl aspartate, did not
noticeably affect acetate release (Figure S6E). Thus, acetate
release occurs as a consequence of histone deacetylation reac-
tions, and acetate recapturing by ACSS2maintains histone acet-
ylation during limited oxygen and serum availability.
DISCUSSION
ACSS2 was recently found to be important for tumor growth
(Schug et al., 2015; Comerford et al., 2014; Mashimo et al.,
2014). However, a quantitative understanding of how it controls
acetate exchange and supports downstream metabolic pro-
cesses is still limited. Here we used innovative stable isotope
tracing approaches to interrogate acetate metabolism in cancer
cells. One of the findings is that cellular acetate freely exchanges
with the medium and that net acetate uptake is controlled by
ACSS2 expression. ACSS2 appears to act in a manner similar654 Cell Reports 18, 647–658, January 17, 2017to hexokinase. Just like hexokinase phosphorylates glucose to
effectively trap it inside the cell to commit it to downstreammeta-
bolism, acetate is captured by ACSS2 and ‘‘primed’’ for meta-
bolic use. In addition to taking up exogenous acetate, our results
demonstrate that ACSS2 recaptures acetate released by deace-
tylation processes to retain it in the cell. It is the combination of
these two activities that determines the net acetate uptake rate.
An important aspect of our work is the determination of ace-
tate utilization fluxes. For example, we were able to estimate
mitochondrial utilization from the reduction in net acetate uptake
upon ACSS1 silencing. This revealed that approximately one-
third of the consumed acetate is dedicated for mitochondrial
use in BT-474 cells, presumably mostly for oxidation but,
perhaps, also for mitochondrial protein acetylation (Baeza
et al., 2016). A major consumer of acetate carbon in the cytosol
is fatty acid biosynthesis. We find that, in high serum, hypoxia
lowers fatty acid biosynthesis, in line with earlier observations
(Kamphorst et al., 2013; Young et al., 2013). In hypoxia and
low serum, on the other hand, despite reduced growth of both
MDA-MB-468 and BT-474 cells, fatty acid biosynthesis is signif-
icantly elevated. (Figures 3E and 3F). This may explain the
increased efficiency of lipogenic inhibitors under these condi-
tions (Schug et al., 2015; Peck et al., 2016). In both cell lines,
the demand for lipogenic AcCoA alone exceeds acetate uptake
by at least 2-fold. The cycling between acetate and acetyl-CoA
Figure 6. ACSS2 Recaptures Acetate Released from Histone
Deacetylation
(A) Western blot of AcH3 and AcH4 in MDA-MB-468 cells upon transfection
with SCR or ACSS2 siRNAs. Cells were cultured under the indicated condi-
tions for 48 hr after transfection under either condition.
(B) Bar plot of the same data, with AcH3 normalized to histone H3 and AcH4 to
histone H4, with normalized values expressed relative to the scrambled RNA.
(C) Acetate release by MDA-MB-468 cells transfected with SCR or ACSS2
siRNAs and with or without 50 mM panobinostat for 6 hr in low oxygen and
serum.
(D) The same for BT-474 cells but with 8-hr incubation.
(E) Schematic of acetate metabolism in oxygen- and serum-limited cancer
cells.
For (B)–(D), data are mean ± SD (n = 3); *p < 0.05, **p < 0.01.
See also Figure S6.and exchange of intracellular acetate with the medium prohibits
accurate quantification of the flux from acetate into fatty acids
(Fan et al., 2013), but given the avid and preferential labeling of
lipogenic AcCoA from acetate (Figure 1H; Figure S1C), it likely
consumes most of the acetate taken up.
To investigate the use of exogenous acetate in the nucleus, we
analyzed labeling of histone-bound acetate. This labeling is
representative of the aggregate of the histone acetate pool
because we measure total (tail and core) histone-bound acetate
by subjecting isolated histones to hydrolysis to release bound
acetate (Tumanov et al., 2016). This approach enables compar-
ison of the nuclear acetate pool versus other pools in the cells in
terms of gross fluxes and pool sizes. As expected, histone-
bound acetate labeled substantially from U-13C-glucose and,
to a lesser extent, from U-13C-glutamine under normoxic condi-
tions (Evertts et al., 2013; Lee et al., 2014). The relative contribu-
tion from U-13C-glutamine increased in hypoxia, showing that
reductive carboxylation in addition to fatty acids also affects his-
tone acetylation. In line with our observation that the combined
mitochondrial and lipogenic two-carbon demand exceeds up-
take of exogenous acetate, we did not observe substantial label-
ing from U-13C-acetate under either normoxic or hypoxic condi-
tions and certainly less than what is observed for lipogenic
AcCoA. This agrees with a recent study demonstrating the inef-
ficient use of acetate-derived AcCoA for histone acetylation
(Zhao et al., 2016). Supplementing free fatty acids to reduce lipo-
genesis increased histone-bound acetate labeling from exoge-
nous U-13C-acetate (Figures 3I and 3J). An explanation for our
observations is that the majority of exogenous acetate is acti-
vated to AcCoA, either by the mitochondrial ACSS1 or the cyto-
solic ACSS2, before it can reach the nucleus. Because of the
high demand of AcCoA-consuming pathways, especially lipo-
genesis, much of the produced AcCoA is used before it can
find its way into the nucleus.
The fact that we can measure overall histone-bound acetate
labeling and that exogenous acetate is preferentially used for
lipogenesis relative to nuclear histone acetylation provides a
fundamental insight into metabolic compartmentalization. His-
tone-bound acetate can be regarded as a proxy for nuclear
AcCoA, and lipogenic AcCoA is representative of the cytosolic
AcCoA pool. It is thought that metabolites, including AcCoA, in
the cytosol and nucleus freely equilibrate. If this occurs on a large
scale, this would result in identical labeling patterns of the
cytosolic and nuclear AcCoA pools. However, we observe strik-
ing differences in their steady-state labeling patterns, indicating
that exchange is fairly limited and that the pools aremostly main-
tained separately. This gives further credence to the notion that
local consumption of AcCoA is too rapid to allow extensive ex-
change between AcCoA in the separate compartments to occur.
An important finding of this work is that the nuclear localization
of ACSS2, which increases in low oxygen and serum, prevents
loss of histone deacetylation. We find that ACSS2 staining is
prominent in tumors of the MMTV-PyMT model of breast cancer
and that the intensity of nuclear staining increases in the hypoxic
regions of the tumor (Figures 4C and 4D). Given that cells in these
regions also likely experience low nutrient availability, it is plau-
sible that retention of acetyl units by ACSS2 to maintain histone
acetylation is a relevant mechanism in vivo. Although the depthCell Reports 18, 647–658, January 17, 2017 655
of metabolic analysis will be less in in vivo tracing experiments,
and comparison of perfused and hypoxic regions is far from triv-
ial, it may be valuable to further explore certain aspects of ace-
tate metabolism. For example, prolonged infusion with 13C-ace-
tatemay help to assess the propensity to incorporate the label as
a function of ACCS2 expression. Additionally, to investigate ac-
etate recapturing by ACSS2 in tumors, mice xenografted with
either high or low ACSS2-expressing isogenic tumors could be
given a bolus of 13C-acetate. This would lead to higher fractional
acetate labeling in high ACSS2 tumors than in lowACSS2 tumors
because, in the latter, tumor cells release more unlabeled ace-
tate. Co-administration of an HDAC inhibitor would reduce the
unlabeled acetate in the low ACSS2 xenografts and increase
fractional labeling.
In conclusion, our work shows that ACSS2 serves a dual func-
tionduringoxygenand serum limitation. It facilitates consumption
of extracellular acetate as an alternative carbon source, but the
increased nuclear localization also enables cells to retain much
of their endogenously produced acetate. ACSS2, in essence, ‘‘re-
cycles’’ two-carbonunitswhennutrient availability is low,which is
especially relevant in the poorly perfused, hypoxic areas of the tu-
mor. It allows cells tomaintain sufficient acetylationof histones, to
prevent initiation of apoptosis, and to maintain growth (Lyssiotis
and Cantley, 2014; Lee et al., 2014). This knowledge may inform
the ongoing evaluation of ACSS2 as a therapeutic target.
EXPERIMENTAL PROCEDURES
Cell Culture
Cell lines were from the ATCC and routinely passaged in DMEM (HyClone) with
25 mM glucose and 2 mM L-glutamine supplemented with 10% (v/v) fetal
bovine serum (FBS)(Gibco) and split at 80% confluence. Cells were routinely
checked for mycoplasma. Experiments were performed in DMEM with
10 mM glucose and 2 mM glutamine supplemented with 1% or 10% dialyzed
FBS (DFBS) (Sigma). Hypoxia was achieved with a hypoxic chamber (Hypo-
xystation H35, Whitley Scientific) at 1% O2, 37
C, and 5% CO2. Cells and me-
dium were equilibrated in the chamber overnight before the experiment. For
experiments, cells were seeded in 6-well plates 24 hr before the experiment
to reach 80% confluency at the end of the experiment. 3 ml of medium was
used per well. Cell growth was determined by packed cell volume (PCV)
(Sartorius Volupac).
Determination of 13C Enrichment in Lipogenic AcCoA
Fatty acid labeling was performed as published previously (Tumanov et al.,
2015). Briefly, DMEM with U-13C-glucose (10 mM) and U-13C-glutamine
(2 mM) and/or U-13C-acetate (Sigma) was used as indicated. After 48–72 hr
of incubation, the medium was aspirated, and cells were washed twice with
2 ml PBS and quenched with 0.75 ml 1:1 v/v PBS:methanol at 20C. Then,
the extraction solvent after cell scraping was transferred to glass tubes, and
the total fatty acids (free and lipid-bound) were extracted in 0.5 ml chloroform
(20C) and dried under nitrogen gas. Lipids were saponified and methylated
with 80 mL toluene, 600 mL methanol, and 120 mL methanolic-HCl, followed
by vortexing and incubation at 100C for 60 min. Fatty acid methyl esters
were extracted with 400 mL water and 300 mL hexane, and the hexane fraction
analyzed by GC-MS (Tumanov et al., 2015). Lipogenic AcCoA 13C enrichment
was derived from fatty acid labeling by determining the best fit with computed
binomial distributions based on a range of AcCoA labeling enrichments (Kam-
phorst et al., 2014; Tumanov et al., 2015).
Medium Acetate Quantification
Acetate was derivatized as before (Tumanov et al., 2016). Briefly, 50 mL
1-propanol was added to 200 mL medium in a 2-mL microfuge tube. 40 mL
1 mM 2H3-acetate (Sigma) was added, and the tube was placed on ice in656 Cell Reports 18, 647–658, January 17, 2017the fume hood, followed by 50 mL pyridine and 5 min of incubation on ice.
Next, 100 mL 1 M NaOH was added, followed by 30 mL methyl chloroformate
(MCF), vortexing for 20 s, and, finally, addition of 300 mL of tert-butyl
methyl ether (MTBE). Samples were vortexed for 2 min and centrifuged at
10,000 3 g for 5 min. The top layer was transferred to GC-MS vials and
analyzed with an Agilent 7890B GC and an Agilent 7000 Triple Quadrupole
GC-MS system with a Phenomenex ZB-1701 column (30 m 3 0.25 mm 3
0.25 mm). Data were extracted with Agilent Mass Hunter B.06.00 software,
fromMS intensities of mass-to-charge ratio (m/z) 61 and 63 ions, correspond-
ing to 12C- and 13C-acetate, respectively, which were quantified with 2H3-ac-
etate (m/z of 64).
Metabolite Extraction and Analysis by LC-MS
Cellular metabolites were extracted as reported previously (Mackay et al.,
2015). Analysis was performed with a Q-Exactive Orbitrap mass spectrometer
(Thermo Scientific) and a Thermo Ultimate 3000 high-performance liquid
chromatography (HPLC) system. HPLC consisted of a ZIC-pHILIC column
(SeQuant, 150 3 2.1 mm, 5 mm, Merck) with a ZIC-pHILIC guard column
(SeQuant, 203 2.1 mm) and an initial mobile phase of 20% 20mM ammonium
carbonate (pH 9.4), and 80% acetonitrile. Cell extracts (5 ml) were injected,
and metabolites were separated over a 15-min mobile phase gradient,
decreasing the acetonitrile to 20%, at a flow rate of 200 mL/min and column
temperature of 45C. Total analysis time was 23 min. The mass range was
75–1,000 m/z at 35,000 resolution (at 200 m/z), with polarity switching for
both positive and negative ion analysis. Lockmasseswere used, andmass ac-
curacy was below 5ppm. Data were processed with MAVEN software (Mela-
mud et al., 2010).
Western Blotting
Protein lysates were prepared in radioimmunoprecipitation assay (RIPA) buffer
(Pierce) with protease inhibitor cocktail (Sigma), and total protein concentra-
tion was determined by protein assay (Bio-Rad). Proteins were separated us-
ing precast NuPAGE gels (Invitrogen, Life Technologies) and transferred onto a
nitrocellulose membrane. Protein detection and quantification were done with
a LI-COROdyssey infrared flatbed scanner (LI-CORBiosciences). The primary
antibodies used were as follows: anti-ACSS1, 1:1,000 (Sigma, SAB1400745);
anti-b-tubulin, 1:5,000 (Sigma, T5201); anti-ACSS2, 1:2,500 (Cell Signaling
Technology, 3658S); anti-acetyl-histone H3, 1:1,000 (Millipore, 06-599); anti-
acetyl-histone H4, 1:1,000 (Millipore, 06-598); anti-histone H3, 1:5,000
(Active Motif, 39763); and anti-histone H4, 1:5,000 (Active Motif, 61521). Sec-
ondary antibodies were IRDye680LT- and IRDye800CW-conjugated (LI-COR
Biosciences).
Acid Extraction of Histones and Histone-Bound Acetate
Cells were cultured in 6-well plates for 48 hr under the indicated conditions, fol-
lowed by washing with cold PBS containing 10 mM sodium butyrate and
50 mM nicotinamide. Nuclei were isolated and histones extracted as
described previously (Lee et al., 2014). 15% SDS-PAGE gels were used for
separating histones and then transferred onto a nitrocellulose membrane
and probed using acetyl-histone-specific antibodies. For GC-MS, isolated his-
tones were hydrolyzed overnight (heating at 95Covernight in 10MNaOH) and
then neutralized with hydrochloric acid. The resulting free acetate was pro-
cessed as before.
Immunofluorescence Analysis and Imaging
Cells were maintained for 48 hr on glass coverslips in the indicated medium.
For fixation, cells were washed three times with PBS and then incubated for
10 min in 4% paraformaldehyde. Cells were washed three times with PBS
and permeabilized for 5 min in PBS containing 0.2% Triton X-100. Following
additional washing (three times) in PBS, samples were blocked in PBS with
0.1% Triton X-100 and 5% FBS for 30 min at room temperature (RT). Samples
were first incubated with anti-ACSS2 (1:200) antibody (Cell Signaling Technol-
ogy) and then with anti-rabbit Alexa Fluor 488 secondary antibodies and DAPI,
washed, and mounted on a glass coverslip using Dako fluorescence mounting
medium. Images were taken on an Olympus FV1000 microscope, and pro-
cessing was done with ImageJ software. Nuclear-to-cytoplasm staining ratio
quantification was done using a macro.
MMTV-PyMT Mice
MMTV-PyMT mice (Guy et al., 1992) were obtained from The Jackson Labora-
tory. Mammary tumors weremeasured by caliper twice weekly, andmice were
culled humanely when tumors reached the clinical endpoint, according to reg-
ulations. Animal experiments were done in accordance with United Kingdom
regulations under project license PPL 70/8645, ethical review (University of
Glasgow), and EU Directive 2010.
Immunohistochemistry and Image Analysis
Serial sections (4 mm) of paraffin-embedded tumor slices were stained for
H&E and immunostained using a Dako autostainer for AceCS1 (ACSS2)
(Cell Signaling Technology, 3658S), CD31 (Abcam, ab28364), and CAIX (No-
vus Biologicals, NB100-417). Slides were analyzed using HALO v2.0 soft-
ware (Indica Labs). Sections stained for CAIX and ACSS2 were analyzed us-
ing Cytonuclear v1.5. Briefly, first hematoxylin staining was set as the nuclear
stain and ACSS2 staining as stain 1, and we manually checked for stain sep-
aration. ACSS2 staining was specified to localize to the nucleus to get the
nuclear staining intensities, and individual cells were assigned to have
weak, moderate, or strong nuclear intensities in a given area based on
pre-defined threshold intensities. This was done for regions of interest
(ROIs) that were manually selected in the CAIX image to represent hypoxic
or normoxic areas.
siRNA and Transfections
All siRNAs were from Dharmacon (GE Life Sciences), reconstituted in sterile
DNase/RNase-free water to a stock concentration of 20 mM, and transfected
using Lipofectamine RNAiMAX reagent (Invitrogen) at a final concentration of
20 nM/well. 48 hr after transfection, cells were seeded for experiments. The
following siGENOME siRNAs were used: scrambled RNA control (non-target-
ing siRNA pool #2, D-001206-14-05), ACSS2 siRNA #1 (D001206-02), ACSS2
siRNA #2 (D001206-03),ACSS1 siRNA #1 (A008549-13), andACSS1 siRNA #2
(A008549-14).
Statistical Analyses
Two-tailed Student’s t tests and Pearson correlation analysis were done using
Graph Pad Prism, version 6. Error bars represent SD of the mean. n is the num-
ber of independent wells for each condition and is mentioned in the figure leg-
ends for each experiment.
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